Johnson & Johnson Vision Presents Data at #Academy23 on ACUVUE MAX 1-Day Contact Lenses
Johnson & Johnson Vision will present data on the ACUVUE OASYS MAX 1-Day brand family of lenses and research on myopia progression, along with learning opportunities and support of Sight for Kids at the Academy 2023 New Orleans meeting, October 11–14.
In celebration of World Sight Day on October 12 and the launch of the company’s new 'Vision Made Possible' campaign, a donation will be made to Sight For Kids on behalf of attendees who visit the company’s booth (#1219), take a photo, and share it using #VisionMadePossible.
Showcasing Clinical Data on ACUVUE OASYS MAX 1-Day and Research on Myopia Progression
- A Large-Scale in Practice Evaluation of a Novel Daily Disposable Spherical Contact Lens. Kurt Moody, OD; Thursday, October 12, 4:30 p.m. – 6:30 p.m. CT; Poster #102, Exhibit Hall D
An in-practice survey was conducted among 81 eye care professionals to evaluate the clinical performance of more than 1,200 patients that were fitted with ACUVUE OASYS MAX 1-Day contact lenses. Findings showed that 90% of eye care professionals agreed that ACUVUE OASYS MAX 1-Day contact lenses provide unprecedented levels of comfort, according to J&J Vision,† and 96% agreed that these lenses deliver on the needs of patients with intense digital device usage, and 91% also agreed that these lenses are their first choice for upgrading patients.†
A Large-Scale in Practice Evaluation of a Novel Daily Disposable Multifocal Contact Lens. Ed Wygonik, OD; October 12, 4:30 p.m. – 6:30 p.m. CT; Poster #101, Exhibit Hall D
The in-practice survey among 81 eye care professionals also examined the clinical performance of ACUVUE OASYS MAX 1-Day MULTIFOCAL contact lenses and included more than 870 patients that were fitted with these lenses. The findings showed 95% of eye care professionals agreed that MAX MULTIFOCAL lenses meet the needs of their presbyopic patients, and 99% agreed it provided patients all-day comfort.† Among the 390 patient surveys received, 3 out of 4 agreed that these lenses provided clear vision at night and crisp,† clear vision in all lighting conditions.†
Can we really distinguish ‘non-responders’ to myopia control interventions? Alex Nixon, OD; Wednesday, October 11, 8:30 a.m. – 10:00 a.m. CT; Room 356 – 357
A sub-analysis of the Low-concentration Atropine for Myopia Progression (LAMP) study, a placebo-controlled trial with children aged 4 to 12 years, was conducted to calculate the efficacy for each intervention by subject age and overall myopia progression. The results showed that, within each intervention group, faster progressors achieved a similar absolute reduction in axial elongation and myopia progression as the slower progressors, and that use of the terms ‘responders’ and ‘non-responders’ is inappropriate.
Elevating Importance of DE&I and Community Through the Empowering Diversity in Optometry Workshop
As a champion for advancing diverse communities in eye care, Johnson & Johnson Vision will be bringing its Empowering Diversity in Optometry series for the first time at Academy 2023 New Orleans, with the theme “The Heart of a Place,” to embrace the unique and diverse culture in New Orleans. This 2-hour workshop will discuss the importance of coming together to serve as a catalyst for change through advancing access to eye care and increasing diverse representation of optometrists. Attendees will be reflecting on their experiences, sharing stories with their peers, and learning from panelists and each other about the importance of contributing to the communities they serve.
References
†JJV Data from the ACUVUE® OASYS MAX 1-Day In-Practice Assessment, with 81 participating Optometrists and 605 spherical and 390 multifocal patients in the US from July to October 2022
‡Lori Tierney is an employee of Johnson & Johnson Vision with oversight as President of Americas.